Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
about
Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.Key Players in Choline Metabolic Reprograming in Triple-Negative Breast CancerMethylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.Graphene Oxide Wrapped SiO2 /TiO2 Hollow Nanoparticles Loaded with Photosensitizer for Photothermal and Photodynamic Combination Therapy.Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma.Evaluating the Effects of Tetrachloro-1,4-benzoquinone, an Active Metabolite of Pentachlorophenol, on the Growth of Human Breast Cancer CellsDecreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitorsCollagen Matrix Density Drives the Metabolic Shift in Breast Cancer Cells.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.Linkage of E2F1 transcriptional network and cell proliferation with respiratory chain activity in breast cancer cells.Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells.Expression of mitochondrial genes MT-ND1, MT-ND6, MT-CYB, MT-COI, MT-ATP6, and 12S/MT-RNR1 in colorectal adenopolyps.A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.Adaptive metabolic rewiring to chronic SFK inhibitionReversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.The β-glucan from Lentinus edodes suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers.Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro.Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3.Remodulating effect of doxorubicin on the state of iron-containing proteins, and redox characteristics of tumor with allowance for its sensitivity to cytostatic agents.Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.Fe-S Clusters Emerging as Targets of Therapeutic Drugs.Poldip2 is an oxygen-sensitive protein that controls PDH and αKGDH lipoylation and activation to support metabolic adaptation in hypoxia and cancer.Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation.BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose.BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancerMetabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway
P2860
Q27317158-1B429691-64EC-4FB5-A994-1B14FAD59784Q28074613-3064CBF6-1754-48AB-B491-CCCD76DC2805Q30842073-74509819-62FF-4E27-A55A-D1D36722B681Q36250335-7624C172-861A-4B5C-BE56-6224C7B56DC8Q36557315-E26C5BB3-096A-418F-8390-7BEFCFD0E128Q36626306-A5695DA2-94FA-4139-94B5-1E926E261C6DQ36916365-A8C79CA2-2A4B-4A60-9BD0-7F64A515F8B9Q37604718-BD0D3C09-B3DB-4BA8-BB73-EAB6E405B026Q37645090-D350A780-E229-4AE9-AB43-E8FDF9ED7664Q38693843-E7F371BD-3507-4493-92FA-99D469988910Q38748855-9A1B44FA-2972-435C-9C19-772B3C0D5B95Q38777012-F76CB5D4-4678-4254-97EC-858330C8E141Q39643937-2BA1897C-56E4-4719-B78A-1E4444DABB21Q39662667-A65C40C0-CE51-4AE9-A6D5-6DC4FFB855A6Q41112245-69965F67-79E5-437E-B6E6-7E6D8C7FA221Q41557835-9F883ECC-37C8-45D2-BDCA-449CBE4747D7Q41878889-929B95F7-F654-4E23-9407-D0B7CD1FC6CDQ42026999-B74309BC-6B69-4203-BD7F-1E04E7232C66Q45770844-E6ABFF86-99A0-464E-8CF3-6D49AC183DD6Q46243045-7BB40962-C43F-4058-9F86-BAD74671572AQ46244123-A4D2AE7D-B764-47B0-A9EF-2B47367DB70CQ46312467-29358585-C1A3-46AB-A371-AAB8AC7826DFQ47206463-E44CCEA9-EA68-4B35-BF58-7F3BF094F80FQ47672384-C3F22EC8-8D3A-45DF-8332-10B01A3F15D1Q48229427-2CC3854E-5726-4A63-8BC0-E06667ECB28EQ49312659-EBBA7DCD-10C9-447A-9052-4D9DACA28C5DQ50056278-4B2FE58D-E6C9-4A67-A30A-9CE49400D39BQ52353599-53333334-8BFF-401C-BF15-A86C02C5268EQ55347754-F029A878-D76C-4E1B-BEC0-22FBE9CB95C1Q55474292-CD049A61-3F3E-4CAE-B6AC-83D57576EB10Q57108388-3912B125-4379-44F7-8654-15562CF6043EQ58750642-6687E182-6A6D-4158-ABDC-4D5CBE48062BQ58765334-F37A5B87-AEA4-4921-B103-69EDA41CE56A
P2860
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@ast
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@en
type
label
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@ast
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@en
prefLabel
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@ast
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@en
P2093
P2860
P1476
Mitochondrial dysfunction in s ...... hway and therapeutic potential
@en
P2093
Hélène Pelicano
Jinyun Liu
Lajos Pusztai
Naima Hammoudi
Peng Huang
P2860
P2888
P356
10.1186/S13058-014-0434-6
P50
P577
2014-09-11T00:00:00Z
P5875
P6179
1029874277